Floatz logo

VIPIVOTIDE TETRAXETAN

Diffuse Pediatric-type High-grade Glioma, H3-wildtype and IDH-wildtype

Memorial Sloan Kettering Cancer CenterSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Diffuse Pediatric-type High-grade Glioma, H3-wildtype and IDH-wildtype cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

VIPIVOTIDE TETRAXETAN is also rated in:

prostate cancerDormant
BB
Indicative ·
71 / 100
View asset →
prostate cancerDormant
BB
Indicative ·
67 / 100
View asset →
prostate adenocarcinomaDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →